---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-023528"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:12:44.442012+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Clearside reports Q3 net loss of $7.8M; OASIS trial shows positive durability for CLS-AX

## Summary
- Q3 2022 net loss of $7.8M ($0.13/share) vs $4.9M loss in Q3 2021; revenue fell to $0.3M from $3.1M.
- OASIS Phase 1/2a met primary safety endpoint; no serious adverse events in 27 wet AMD patients.
- Cohorts 3/4: 88% injection-free to Month 5, 75% to Month 6; >90% reduction in treatment burden.
- Company expects to initiate Phase 2 trial for CLS-AX in wet AMD in Q1 2023.
- Entered royalty interest sale with HealthCare Royalty for up to $65M non-dilutive funding; cash $53.4M, runway into 2024.

## SEC filing metadata
- accession: 0000950170-22-023528
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017022023528/0000950170-22-023528-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017022023528/clsd-20221109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-023528
- JSON: https://secwatch.observer/filing/0000950170-22-023528.json
- Plain text: https://secwatch.observer/filing/0000950170-22-023528.txt

## Key facts
- Earnings Releases
  Clearside Biomedical, Inc. reported the third quarter ended September 30, 2022 results: revenue $0.3 million, net income $7.8 million, EPS $0.13 per share of common stock.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $0.3 million
  - Net income: $7.8 million
  - EPS: $0.13 per share of common stock
  - Result: reported results
  source text: Clearside’s license and other revenue for the third quarter of 2022 was $0.3 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1539029/000095017022023528/0000950170-22-023528-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.